Risk of impaired coagulation in warfarin patients ascending to altitude (>2400 m)

Martha C. Tissot van Patot, Ashley E Hill, Colleen Dingmann, Lawrence Gaul, Kelly Fralick, Uwe Christians, Benjamin Honigman, M. D. Salman

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

Approximately 476,000 people on warfarin therapy visit a resort at altitude (>2400 m) annually in Colorado. Clinicians practicing at altitude have expressed concern that ascent to altitude adversely affects coagulation in patients taking warfarin in both high altitude residents and visitors. We sought to determine the effect of ascent to and descent from altitude on coagulation in warfarin patients, as assessed by the international normalized ratio (INR). A retrospective medical chart review was conducted on all warfarin patients treated between August 1998 and October 2003 at a cardiology clinic in which travel to and from altitude was documented in association with each INR measurement in high altitude residents. Of the 1139 INR measurements in 49 patients, 143 were associated with changes in altitude (in 32 of 49 patients). The odds of an INR measurement being below the prescribed range were 2.7 times (95% CI: 1.2-5.8) higher among warfarin patients with recent ascent to altitude, 2.1 times (95% CI: 1.4-3.2) higher among warfarin patients with atrial fibrillation, and 5.6 (95% CI: 2.3-13.7) times higher among warfarin patients with both atrial fibrillation and recent ascent to altitude. Increasing altitude is a risk factor for subtherapeutic INR in warfarin patients and this risk is doubled in atrial fibrillation patients.

Original languageEnglish (US)
Pages (from-to)39-46
Number of pages8
JournalHigh Altitude Medicine and Biology
Volume7
Issue number1
DOIs
StatePublished - Mar 2006
Externally publishedYes

Fingerprint

Warfarin
International Normalized Ratio
Atrial Fibrillation
Cardiology

Keywords

  • Anticoagulation
  • Atrial fibrillation
  • Hypoxia
  • International normalized ratio
  • Prothrombin time

ASJC Scopus subject areas

  • Medicine(all)
  • Physiology
  • Physical Therapy, Sports Therapy and Rehabilitation
  • Orthopedics and Sports Medicine

Cite this

Tissot van Patot, M. C., Hill, A. E., Dingmann, C., Gaul, L., Fralick, K., Christians, U., ... Salman, M. D. (2006). Risk of impaired coagulation in warfarin patients ascending to altitude (>2400 m). High Altitude Medicine and Biology, 7(1), 39-46. https://doi.org/10.1089/ham.2006.7.39

Risk of impaired coagulation in warfarin patients ascending to altitude (>2400 m). / Tissot van Patot, Martha C.; Hill, Ashley E; Dingmann, Colleen; Gaul, Lawrence; Fralick, Kelly; Christians, Uwe; Honigman, Benjamin; Salman, M. D.

In: High Altitude Medicine and Biology, Vol. 7, No. 1, 03.2006, p. 39-46.

Research output: Contribution to journalArticle

Tissot van Patot, MC, Hill, AE, Dingmann, C, Gaul, L, Fralick, K, Christians, U, Honigman, B & Salman, MD 2006, 'Risk of impaired coagulation in warfarin patients ascending to altitude (>2400 m)', High Altitude Medicine and Biology, vol. 7, no. 1, pp. 39-46. https://doi.org/10.1089/ham.2006.7.39
Tissot van Patot, Martha C. ; Hill, Ashley E ; Dingmann, Colleen ; Gaul, Lawrence ; Fralick, Kelly ; Christians, Uwe ; Honigman, Benjamin ; Salman, M. D. / Risk of impaired coagulation in warfarin patients ascending to altitude (>2400 m). In: High Altitude Medicine and Biology. 2006 ; Vol. 7, No. 1. pp. 39-46.
@article{bd693253a157494d9e7a4a407431d12c,
title = "Risk of impaired coagulation in warfarin patients ascending to altitude (>2400 m)",
abstract = "Approximately 476,000 people on warfarin therapy visit a resort at altitude (>2400 m) annually in Colorado. Clinicians practicing at altitude have expressed concern that ascent to altitude adversely affects coagulation in patients taking warfarin in both high altitude residents and visitors. We sought to determine the effect of ascent to and descent from altitude on coagulation in warfarin patients, as assessed by the international normalized ratio (INR). A retrospective medical chart review was conducted on all warfarin patients treated between August 1998 and October 2003 at a cardiology clinic in which travel to and from altitude was documented in association with each INR measurement in high altitude residents. Of the 1139 INR measurements in 49 patients, 143 were associated with changes in altitude (in 32 of 49 patients). The odds of an INR measurement being below the prescribed range were 2.7 times (95{\%} CI: 1.2-5.8) higher among warfarin patients with recent ascent to altitude, 2.1 times (95{\%} CI: 1.4-3.2) higher among warfarin patients with atrial fibrillation, and 5.6 (95{\%} CI: 2.3-13.7) times higher among warfarin patients with both atrial fibrillation and recent ascent to altitude. Increasing altitude is a risk factor for subtherapeutic INR in warfarin patients and this risk is doubled in atrial fibrillation patients.",
keywords = "Anticoagulation, Atrial fibrillation, Hypoxia, International normalized ratio, Prothrombin time",
author = "{Tissot van Patot}, {Martha C.} and Hill, {Ashley E} and Colleen Dingmann and Lawrence Gaul and Kelly Fralick and Uwe Christians and Benjamin Honigman and Salman, {M. D.}",
year = "2006",
month = "3",
doi = "10.1089/ham.2006.7.39",
language = "English (US)",
volume = "7",
pages = "39--46",
journal = "High Altitude Medicine and Biology",
issn = "1527-0297",
publisher = "Mary Ann Liebert Inc.",
number = "1",

}

TY - JOUR

T1 - Risk of impaired coagulation in warfarin patients ascending to altitude (>2400 m)

AU - Tissot van Patot, Martha C.

AU - Hill, Ashley E

AU - Dingmann, Colleen

AU - Gaul, Lawrence

AU - Fralick, Kelly

AU - Christians, Uwe

AU - Honigman, Benjamin

AU - Salman, M. D.

PY - 2006/3

Y1 - 2006/3

N2 - Approximately 476,000 people on warfarin therapy visit a resort at altitude (>2400 m) annually in Colorado. Clinicians practicing at altitude have expressed concern that ascent to altitude adversely affects coagulation in patients taking warfarin in both high altitude residents and visitors. We sought to determine the effect of ascent to and descent from altitude on coagulation in warfarin patients, as assessed by the international normalized ratio (INR). A retrospective medical chart review was conducted on all warfarin patients treated between August 1998 and October 2003 at a cardiology clinic in which travel to and from altitude was documented in association with each INR measurement in high altitude residents. Of the 1139 INR measurements in 49 patients, 143 were associated with changes in altitude (in 32 of 49 patients). The odds of an INR measurement being below the prescribed range were 2.7 times (95% CI: 1.2-5.8) higher among warfarin patients with recent ascent to altitude, 2.1 times (95% CI: 1.4-3.2) higher among warfarin patients with atrial fibrillation, and 5.6 (95% CI: 2.3-13.7) times higher among warfarin patients with both atrial fibrillation and recent ascent to altitude. Increasing altitude is a risk factor for subtherapeutic INR in warfarin patients and this risk is doubled in atrial fibrillation patients.

AB - Approximately 476,000 people on warfarin therapy visit a resort at altitude (>2400 m) annually in Colorado. Clinicians practicing at altitude have expressed concern that ascent to altitude adversely affects coagulation in patients taking warfarin in both high altitude residents and visitors. We sought to determine the effect of ascent to and descent from altitude on coagulation in warfarin patients, as assessed by the international normalized ratio (INR). A retrospective medical chart review was conducted on all warfarin patients treated between August 1998 and October 2003 at a cardiology clinic in which travel to and from altitude was documented in association with each INR measurement in high altitude residents. Of the 1139 INR measurements in 49 patients, 143 were associated with changes in altitude (in 32 of 49 patients). The odds of an INR measurement being below the prescribed range were 2.7 times (95% CI: 1.2-5.8) higher among warfarin patients with recent ascent to altitude, 2.1 times (95% CI: 1.4-3.2) higher among warfarin patients with atrial fibrillation, and 5.6 (95% CI: 2.3-13.7) times higher among warfarin patients with both atrial fibrillation and recent ascent to altitude. Increasing altitude is a risk factor for subtherapeutic INR in warfarin patients and this risk is doubled in atrial fibrillation patients.

KW - Anticoagulation

KW - Atrial fibrillation

KW - Hypoxia

KW - International normalized ratio

KW - Prothrombin time

UR - http://www.scopus.com/inward/record.url?scp=33645638434&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33645638434&partnerID=8YFLogxK

U2 - 10.1089/ham.2006.7.39

DO - 10.1089/ham.2006.7.39

M3 - Article

C2 - 16544965

AN - SCOPUS:33645638434

VL - 7

SP - 39

EP - 46

JO - High Altitude Medicine and Biology

JF - High Altitude Medicine and Biology

SN - 1527-0297

IS - 1

ER -